CCXI has an explanation. It's in some of their presentations. Something about too much drug triggers some adverse factor. Sounds fishy to me.
I may be wrong, but I believe LBIO's results are for monotherapy only, and they are planning studies with their drug combined with other drugs. Also, in the first quarter, Baker Brothers, Fidelity, Franklin, and Orbimed bought in. Those outfits seem to know their stuff.
The highest acceptable p value in a trial is .05. This means that the chance of the positive result being due to coincidence is 1 out of 20. The lower the p value, the more confident you can be that the positive result was actually due to the effects of the drug. Some trials have a p value of .001, meaning that the chance of the positive result being due to coincidence was 1 out of 1000.
I know a lot of people who lost fig trees over this past winter (in the northeast) because they didn't cover them. When my old fig trees got too big to cover, I at least covered the bottoms with mulch and a tarpaulin to protect the roots from the cold, and never lost any trees.
After the phase 2 trial, the company said that this drug will be tested for so many different conditions that they just don't have the resources to do it. I agree they made a bad deal though .Bayer will cook the books and cheat us.
I would think the deal CELG signed with Astra Zeneca would dampen BMY's interest in CELG ( if they had any interest).
Older people can convert IRA money into a Roth IRA only after they have taken out their Minimum Yearly Distribution from their IRA, if they are 70 and 1/2 years old or older.
It's the same deal for older people. But you have to remember that the extra income might push you into a higher tax bracket, and might trigger or increase the income tax on your Social Security benefits.
Two patients at Penn died of heart failure in 2013 after CAR-T therapy for cancer. The T-cells attacked a heart protein that was not present in the animals used in pre-clinical testing. Carl June in a recent interview said that an on-off switch is needed.
So move on. We're adults here and we take responsibility for our own actions. We don't need you hanging on and worrying about us.
I don't think you realize the significance of the stage 4 ovarian cancer patient's results. I've said this before, but not only did her spleen lesion disappear, but her greatly increased peritoneal fluid cleared. Increased peritoneal fluid is caused by metastatic tumor nodules that have seeded the peritoneal membranes. This means that those lesions have also regressed. This is unheard of in stage 4 ovarian cancer, and I believe it's why Dana Farber asked CTIX to write a paper on K.
I bought MEIP because of the top line data on phase 2 for AML.. The slide shows that the longer the treatment period, the greater the conversion to CR. So far, not one patient with a CR has relapsed. The investigator said he has never seen results like this in AML. I know AML is a smaller market than MDS, but I was surprised at the reaction to the MDS data. More complete data on phase 2 for AML is due in June. I doubled my holdings yesterday. Couldn't resist at 2 dollars a share. I think insurance companies might insist on treatment with pracinostat before they will pay for CAR-T therapy.